Overview

* Roivant fiscal Q1 revenue declines significantly, reflecting increased R&D expenses

* Company reports net loss from continuing operations of $273.9 mln

* Roivant completed $1.5 bln share repurchase program, reducing shares by over 15%

Outlook

* Roivant expects brepocitinib DM trial data in H2 2025

* Company anticipates brepocitinib NIU trial results in H1 2027

* Roivant plans new $500 mln share repurchase program

* Company maintains cash runway into profitability

Result Drivers

* R&D EXPENSES - Increased by $32.4 mln due to program-specific costs and personnel-related expenses, primarily driven by anti-FcRn franchise

* SHARE REPURCHASE - Completed $1.5 bln share repurchase program, reducing shares by over 15%

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 $2.17

Revenue mln

Q1 EPS -$0.33

Q1 Net -$273.91

Income mln

Q1 Miss -$284.92 -$255.80

Income mln mln (4

From Analysts

Operatio )

ns

Q1 $287.09

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Roivant Sciences Ltd ( ROIV ) is $17.50, about 34.3% above its August 8 closing price of $11.49

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)